DEF 14A: Safe and Green Development Corporation Seeks Stockholder Approval for Increased Share Authorization and Arena Transactions

Safe and Green Development Corporation is holding a special meeting to seek stockholder approval for increasing authorized common stock and for transactions with Arena Investors and Arena Business Solutions Global SPC II, LTD.

Summary

• Safe and Green Development Corporation is convening a Special Meeting of Stockholders on November 4, 2024, to vote on four proposals.
• The first proposal seeks approval to amend the company's Amended and Restated Certificate of Incorporation to increase the authorized number of common stock shares from 50,000,000 to 100,000,000.
• The second proposal seeks approval for the issuance of 20% or more of the company's outstanding common stock as of August 12, 2024, pursuant to a securities purchase agreement with Arena Investors.
• This includes shares issued upon conversion of debentures and exercise of warrants.
• The third proposal seeks approval for the issuance of 20% or more of the company's outstanding common stock as of August 12, 2024, pursuant to a private equity line purchase agreement with Arena Business Solutions Global SPC II, LTD (Arena Global).
• This includes commitment fee shares issued or issuable to Arena Global.
• The fourth proposal is to approve the adjournment of the Special Meeting to a later date, if necessary, to permit further solicitation of proxies if there are insufficient votes for the other proposals.
• As of September 16, 2024, there were 18,733,713 shares of Common Stock outstanding and entitled to vote.
• The Board of Directors recommends voting FOR all four proposals.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting the facts of the proposals for stockholder vote. While the transactions provide access to capital, they also carry risks of dilution and market price impact.

Positives

• Increasing the authorized number of shares provides the company with flexibility for future business and financial purposes, including equity incentives and potential strategic transactions.
• The Arena transactions provide access to capital through convertible debentures and an equity line of credit.
• The ELOC Purchase Agreement with Arena Global provides a reliable source of capital for working capital and general corporate purposes.

Negatives

• Approval of the proposals could lead to dilution of existing stockholders' ownership interests.
• The sale of shares into the public market could materially and adversely affect the market price of the common stock.
• Failure to approve the proposals could limit the company's ability to raise capital and pursue strategic transactions.

Risks

• The market price of the company's common stock could be negatively impacted by the issuance of new shares.
• Existing stockholders could experience dilution of their ownership interests.
• The company's ability to meet Nasdaq's stockholders' equity requirements could be adversely affected if the proposals are not approved.
• The company is prohibited from entering into a Variable Rate Transaction (other than the ELOC Purchase Agreement described below) until such time as no Debentures remain outstanding.

Future Outlook

The company anticipates seeking future equity financing opportunities and will evaluate opportunities that are presented to it. The company believes that the Authorized Common Stock Increase will help ensure that it has sufficient authorized shares available for issuance to allow it to pursue equity financings if the Board of Directors determines that it would be in the company's best interests based on its working capital needs and prevailing market conditions.

Management Comments

• On behalf of Safe and Green Development Corporation, I thank you for your ongoing interest and investment in our company.
• The Board believes that if at the Special Meeting, the number of votes represented by shares of the Common Stock, present or represented and voting in favor of Proposal No. 1 (the Authorized Common Stock Increase Proposal), Proposal 2 (the Arena Offering Proposal) and/or Proposal 3 (the ELOC Issuance Proposal) is insufficient to approve any of such proposals or establish a quorum, it is in the best interests of the stockholders to enable the Board to continue to seek to obtain a sufficient number of additional votes to approve such proposals.

Industry Context

Many companies in similar financial situations use equity lines of credit and convertible debentures to raise capital. The approval sought is standard practice to ensure compliance with Nasdaq listing rules when issuing a significant portion of shares.

Comparison to Industry Standards

• Increasing authorized shares is a common practice for companies seeking financial flexibility, similar to actions taken by other publicly traded companies to facilitate future financings or acquisitions.
• The terms of the Arena transactions, including the interest rate, conversion price, and warrants, are within the range of what is typically seen in similar financing arrangements for small-cap companies.
• The ELOC Purchase Agreement is similar to equity lines of credit used by other companies to provide access to capital over a period of time.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution of their ownership interests.
• Employees may benefit from the increased financial stability and potential for equity incentives.
• The company's ability to execute its business plan and create value for stakeholders depends on the approval of these proposals.

Next Steps

• Stockholders to vote on the proposals at the Special Meeting on November 4, 2024.
• The company to file final results in a Current Report on Form 8-K within four business days of the Special Meeting.
• If approved, the company will proceed with the issuance of shares and other actions related to the Arena transactions and the ELOC Purchase Agreement.

Key Dates

Keywords

common stock, Arena Investors, ELOC, authorized shares, proxy statement, issuance, debentures, warrants, stockholders, approval